Overview
Cell Culture History
Discovery Labware
News and Events
Locations
Distributors
FAQs
Careers
Contact Us
Email Sign Up

Events Calendar


International Society for the Study of Xenobiotics (ISSX) 2014
October 19 - 23, 2014
Hilton San Francisco Union Square , Booth # 502
San Francisco, CA
Additional Information:

This session is an industry-supported symposium. Although not an official part of the 19th North American ISSX/29th JSSX Meeting, this program has been reviewed and its presentation permitted by the meeting organizers.

Join our Tutorial

Wednesday, October 22 |  7:30 a.m. – 8:30 a.m.

At Corning, we continue to invent novel technologies to facilitate pharmaceutical industry to investigate drug ADME. We will be presenting a tutorial on two new products and their applications.

Corning® HepatoCells Products: Presented by Rongjun Zuo, Ph.D., Development.
Primary human hepatocytes as the “Gold Standard” for studying metabolic fate of xenobiotics bear inherent limitations such as large lot-to-lot variability, short life span, tendency to dedifferentiate in culture, and limited supply of high quality raw materials. To overcome these shortcomings, Corning developed HepatoCells products from primary human hepatocytes. Corning HepatoCells products are a renewable source of hepatocyte like cells, which retain most of the physiological properties of their parental hepatocytes, show mature hepatocyte-like morphology, and have been characterized for CYP3A4, 1A2, and 2B6 induction response to prototypical inducers. In this tutorial, we will provide an overview of the product characterization and application of using Corning HepatoCells products for prediction of clinical CYP3A4 inducers.

Corning TransportoCells™ Products: Presented by Na Li, Ph.D.
As a key determinant of drug pharmacokinetics, transporter mediated drug-drug interaction has been brought significant attention of pharmaceutical industry and regulatory authorities. Corning offers a comprehensive list of tools to support drug transporter studies. Specially, Corning TransportoCells products was recently introduced to support in vitro assessment of SLC transporter- involved drug drug interactions. This new model provides a convenient “thaw and go” cell- based model with robust activity and consistent performance. In this tutorial, we will provide an overview of the product characterization and application of in vitro to in vivo correlation using TransportoCells products. Validation data will also be presented for the newly available transporters in the product line, including PEPT1, PEPT2, NTCP, and OATP2B1.

Corning Poster Presentations   

Monday, October 20 | 4:30 p.m. – 6:00 p.m.

P156 “Use of Nominal or Time-averaged Media Concentrations of Test Compounds in Plated Hepatocyte Induction Assays to Determine EC50 Values and Relative Induction Scores: Impact on Prediction of CYP3A4 Induction Potential In vivo”. Presented by George Zhang, Ph.D., Senior Staff Scientist.

P189 “Epidermal Growth Factor Preferentially Down-regulates Basal, But Not Induced CYP3A4cyp3a4 at Supra-physiological Concentrations in Plated Human Hepatocytes”. Presented by George Zhang, Ph.D., Senior Staff Scientist.

P196 “An In vitro Screening Tool for Predicting Clinical CYP3A4 Induction”. Presented by Rongjun Zuo, Ph.D., Staff Scientist, Development.

Tuesday, October 21 | 12:30 p.m. – 2:00 p.m.

P239 “Corning® HepatoCells Products Cells Closely  the Behavior of Parental Cells for Predicting Hepatotoxicity”. Presented by Ronald A. Faris, Ph.D., Director of Cell Biology.

P232 “Corning HepatoCells Products: An Alternative Hepatic Model for In vitro ADME/Tox Applications”. Presented by Rongjun Zuo, Ph.D., Staff Scientist, Development.

P252 “Characterization of Corning HepatoCells Products for Drug Uptake Transport Assay”. Presented by Rongjun Zuo, Ph.D., Staff Scientist, Development.

Wednesday, October 22 | 12:30 p.m. – 2:00 p.m.

P443 “Use of a Novel Cell-based Model to Predict Hepatic Clearance of Statins: In vitro to In vivo Correlation”. Presented by Na Li, Ph.D., Staff Scientist, Development.

P454 “A Novel Cell-based SLC Transporter Model: Validation of OATP2B1 and NTCP TransportoCells Products”. Presented by Na Li, Ph.D., Staff Scientist, Development.

P498 “Development and Characterization of a Novel Cell-based Model to Study Peptide Transporters 1 and 2- Structural Insights into Substrate / Inhibitor Recognition of Peptide Transporters”. Presented by Na Li, Ph.D., Staff Scientist, Development.

In Vitro Models for Studying Angiogenesis
October 30, 2014
Online , Presenter: Paula Flaherty
Time: 12:00 - 1:00 pm
Additional Information:

Angiogenesis is the process by which a new blood supply is established from pre-existing blood vessels. It is initiated by degradation of vessel basement membrane, endothelial cell proliferation, invasion, and directional migration towards chemoattractants, tube formation, and finally the establishment of a new vasculature.

Register now to learn how Corning products can be used to help you more accurately replicate and investigate the specific stages of angiogenesis through standardized and quantitative in vitro cell-based assays.

  • HUVEC-2 Endothelial Cells - Widely studied endothelial cells that have been pre-screened for responsiveness to VEGF, a prototypic stimulator of angiogenesis
  • ECMs and Chemoattractants - ECMs, like Corning® Matrigel® Matrix, provide key pro-angiogenic chemoattractants for optimal EC propagation, attachment, differentiation, and other key functions as well as provide support and structure for more in vivo-like tumor angiogenesis modeling
  • Endothelial Cell Invasion and Migration Assays - Corning FluoroBlok™ microporous permeable supports coated with our unique extracellular matrix proteins allow quantitation of endothelial cell migration and invasion, automated screening and reproducible quantification of prospective pro- and anti-angiogenic compounds
  • Endothelial Cell Tube Formation Assay - A rapid assay system, this approach is relatively easy to set up, is quantifiable and allows for direct screening of angiogenic compounds for their effects on endothelial cell tube formation

About our Presenter
Paula Flaherty is a Technology Manager at Corning Life Sciences. Her team develops strategy and products focused on the modulation of in vitro cell behavior using extracellular matrix, media, vessel design, and growth factors. Prior to joining Corning Life Sciences, Paula studied retinal degeneration at the Berman-Gund Laboratory, Harvard Medical School in Boston, MA. She received her bachelor’s degree in Microbiology from the State University of New York and is an In Vitro Cell Biology Fellow, W. Alton Jones Cell Science Center in Lake Placid, NY.

Note: All Corning webinar presentations are available on our website on demand for viewing at your convenience.

Return to Top